Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D05RQY
|
|||
| Former ID |
DIB011777
|
|||
| Drug Name |
MM-093
|
|||
| Synonyms |
ABI-001; Recombinant human alpha fetoprotein (autoimmune diseases), Merrimack; RhAFP (autoimmune diseases), Merrimack; Recombinant human alpha-fetoprotein (autoimmune disease), GTC Biotherapeutics
Click to Show/Hide
|
|||
| Indication | Autoimmune diabetes [ICD-11: 5A10] | Phase 2 | [1] | |
| Company |
Merrimack Pharmaceuticals
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Alpha-fetoprotein (AFP) | Target Info | Modulator | [2] |
| KEGG Pathway | Hippo signaling pathway | |||
| Pathway Interaction Database | p73 transcription factor network | |||
| FOXA2 and FOXA3 transcription factor networks | ||||
| Glucocorticoid receptor regulatory network | ||||
| Direct p53 effectors | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT00458146) A Phase 2 Study to Evaluate the Efficacy and Safety of 60mg of MM-093 in Patients With Active Rheumatoid Arthritis. U.S. National Institutes of Health. | |||
| REF 2 | MM-093, a recombinant human alpha-fetoprotein for the potential treatment of rheumatoid arthritis and other autoimmune diseases. Curr Opin Mol Ther. 2007 Dec;9(6):603-10. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.